Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Long Term Extension Program
NCT00625378Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2007
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of sorafenib in Neoplasm, hepatocellular carcinoma (HCC), breast cancer, sponsored by Bayer. Started Dec 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
Neoplasmhepatocellular carcinoma (HCC)breast cancer
Beyond the preview
Go deeper on NCT00625378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625378.